6月30日，全球第三大专注于多肽的CRDMO服务商泰德医药(03880.HK)在港交所挂牌上市。截至发稿，该股盘中大涨5.23%，引发市场关注。
泰德医药此次IPO获得投资者热烈追捧，公开发售部分获301.15倍超额认购。公司定价每股30.60港元，发行1680万股，募资净额约4.29亿港元。上市首日开盘价为30.3港元，略低于发行价，但随后股价迅速拉升。
分析人士认为，泰德医药股价上涨主要有以下几个原因：首先，公司是全球第三大专注于多肽的CRDMO，市场份额达1.5%，在行业中具有领先地位。其次，公司业务覆盖从早期发现到商业化生产的全周期服务，在GLP-1等热门领域拥有9个NCE项目。再者，公司计划利用此次募资在美国和中国扩大产能，以把握GLP-1药物市场快速增长的机遇。最后，公司在多个国家建立了稳定的客户关系，海外业务增长强劲，特别是美国市场收入占比已超过50%。这些因素都为公司未来发展提供了良好基础，增强了投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.